跳到正文
原文
Medical Xpress·· 2026-10-09精选AI 评分70

UCL研究:免疫雾或可在肿瘤形成前数年预示肺癌风险

'Immune fog' may flag lung cancer risk years before tumor develops

AI 导读

伦敦大学学院团队在Nature发表研究,发现调节性T细胞会在肺癌确诊前数月或数年逐渐积聚,形成可能干扰免疫系统识别肿瘤的免疫雾。原型血液检测可监测该信号,动物实验中靶向药物逆转了免疫抑制效应,使肺癌发生率减半。

推荐理由

研究揭示调节性T细胞在肺癌确诊前数年即逐渐积聚,或可借血液监测识别高风险人群,并为早期拦截癌前病变提供新思路。

正文 · 原文
Clearing 'immune fog' could stop lung cancer before diagnosis
Schematic of matched scRNA-seq and scTCR-seq of CD4+ T cells from paired PBMC and HGLs. Credit: Nature (2026). DOI: 10.1038/s41586-026-11066-6

A 'rising fog' may cloud the immune system's ability to detect tumors and may be the key to tackling lung cancer that is developing years before diagnosis. The team at University College London (UCL) followed this signal using prototype blood tests and reversed it using drugs.

Led by associate professor James Reading and professor Sam Janes, the study published in Nature potentially opens up new ways to intercept the disease in its early, precancerous stages.

Early intervention

There are around 32,800 lung cancer deaths in the U.K. every year. Only about 1 in 10 (11.1%) people diagnosed with lung cancer are predicted to survive for 10 years or more. By the time the disease causes noticeable symptoms, and in cases of advanced cancer, it is harder to treat.

Reading, an associate professor at UCL, said, "We urgently need new ways to prevent lung cancer in people at high risk of developing the disease. There was a moment when multiple members of my team were telling me that they'd spotted the same unusual regulatory T cell activity.

"What excited us most was that these cells weren't just signaling that cancer might be developing: It was also possible to target this immune fog to intervene and stop tumors from forming, which could give us new ways to prevent lung cancer."

Understanding the precursors of cancer

The team carefully studied blood and tissue samples collected from people taking part in long-running lung cancer surveillance and screening studies. They also analyzed similar processes in mice to understand what makes precursors of lung cancer (called precancers or lesions) develop into full-fledged tumors.

They discovered that regulatory T cells (Tregs), a set of specialized cells that form part of the immune system, gradually built up months or years before cancer developed.

Tregs typically hold back other cells, pausing their activity, which could be allowing precancers to slip through the cracks and develop into lung cancer unchallenged by the immune system.

Identifying people at risk

Using prototype blood tests, the team found that monitoring Treg levels could help identify people at increasing risk of lung cancer or patients with an early form of it. They also explored using targeted cancer drugs to reverse and disperse the Treg "fog" and found that a drug targeting specific immune processes could reverse the Tregs' immune-suppressing effect.

This approach halved the proportion of animals that developed lung tumors in laboratory experiments and prevented the formation of all large tumors.

Dr. Charlotte Durkin, associate director of molecular and cellular medicine at MRC, said, "This study provides valuable new insight into the early stages of lung cancer development. By identifying mechanisms that could both signal increased risk and offer opportunities for intervention, this research highlights the potential of discovery science to underpin new approaches to cancer prevention and early detection."

Cancer interception

Janes, interim dean of the Faculty of Population Health Sciences at UCL, said, "We're moving from largely treating cancer when it develops toward tackling the precancerous disease. This is called cancer interception, an exciting and emerging area of research which we hope will stop some precancers from ever becoming cancers in the first place."

Dr. Catherine Elliott, director of research and partnerships at Cancer Research UK, said, "This work is helping lay the foundations for more personalized approaches to cancer prevention, detection and interception. It's an important step toward understanding the interaction between the immune system and the development of lung cancer, and ultimately how we might stop cancer before it starts."

Publication details

Samuel Gamble et al, A preinvasive regulatory T cell axis for lung cancer interception, Nature (2026). DOI: 10.1038/s41586-026-11066-6

Journal information: Nature

Who's behind this story?

Lisa Lock

Lisa Lock

BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: 'Immune fog' may flag lung cancer risk years before tumor develops (2026, October 8) retrieved 8 October 2026 from https://medicalxpress.com/news/2026-10-immune-fog-flag-lung-cancer.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com